158424 Division of Cardiothoracic Surgery, University of Miami, FL, USA.
3989 Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
Innovations (Phila). 2021 Jan-Feb;16(1):43-51. doi: 10.1177/1556984520971775. Epub 2020 Dec 3.
Risk-scoring systems for surgical aortic valve replacement (AVR) were largely derived from sternotomy cases. We evaluated the accuracy of current risk scores in predicting outcomes after minimally invasive AVR (mini-AVR). Because transcatheter AVR (TAVR) is being considered for use in low-risk patients with aortic stenosis, accurate mini-AVR risk assessment is necessary.
We reviewed 1,018 consecutive isolated mini-AVR cases (2009 to 2015). After excluding patients with Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) scores ≥4, we calculated each patient's European System for Cardiac Operative Risk Evaluation (EuroSCORE) II, TAVR Risk Score (TAVR-RS), and age, creatinine, and ejection fraction score (ACEF). We compared all 4 scores' accuracy in predicting mini-AVR 30-day mortality by computing each score's observed-to-expected mortality ratio (O:E). Area under the receiver operating characteristic (ROC) curves tested discrimination, and the Hosmer-Lemeshow goodness-of-fit tested calibration.
Among 941 patients (mean age, 72 ± 12 years), 6 deaths occurred within 30 days (actual mortality rate, 0.6%). All 4 scoring systems overpredicted expected mortality after mini-AVR: ACEF (1.4%), EuroSCORE II (1.9%), STS-PROM (2.0%), and TAVR-RS (2.1%). STS-PROM best estimated risk for patients with STS-PROM scores 0 to <1 (0.6 O:E), ACEF for patients with STS-PROM scores 2 to <3 (0.6 O:E), and TAVR-RS for patients with STS-PROM scores 3 to <4 (0.7 O:E). ROC curves showed only fair discrimination and calibration across all risk scores.
In low-risk patients who underwent mini-AVR, current surgical scoring systems overpredicted mortality 2-to-3-fold. Alternative dedicated scoring systems for mini-AVR are needed for more accurate outcomes assessment.
外科主动脉瓣置换术(AVR)的风险评分系统主要来源于胸骨切开术病例。我们评估了当前风险评分系统在预测微创 AVR(mini-AVR)术后结果中的准确性。由于经导管主动脉瓣置换术(TAVR)正被考虑用于主动脉瓣狭窄的低危患者,因此需要准确评估 mini-AVR 风险。
我们回顾了 1018 例连续的孤立性 mini-AVR 病例(2009 年至 2015 年)。排除 STS 预测死亡率(STS-PROM)评分≥4 的患者后,计算每位患者的欧洲心脏手术风险评估系统(EuroSCORE)II、TAVR 风险评分(TAVR-RS)和年龄、肌酐和射血分数评分(ACEF)。通过计算每个评分的观察到的与预期死亡率之比(O:E),比较所有 4 个评分在预测 mini-AVR 30 天死亡率方面的准确性。接受者操作特征(ROC)曲线下面积评估了判别能力,Hosmer-Lemeshow 拟合优度检验评估了校准能力。
在 941 例患者(平均年龄 72±12 岁)中,30 天内有 6 例死亡(实际死亡率为 0.6%)。所有 4 种评分系统在 mini-AVR 后均高估了预期死亡率:ACEF(1.4%)、EuroSCORE II(1.9%)、STS-PROM(2.0%)和 TAVR-RS(2.1%)。STS-PROM 对 STS-PROM 评分 0 至<1 的患者风险估计最佳(0.6 O:E),ACEF 对 STS-PROM 评分 2 至<3 的患者风险估计最佳(0.6 O:E),TAVR-RS 对 STS-PROM 评分 3 至<4 的患者风险估计最佳(0.7 O:E)。ROC 曲线显示,所有风险评分的判别能力和校准能力仅为中等。
在接受 mini-AVR 的低危患者中,当前的外科评分系统高估了死亡率 2 至 3 倍。需要为 mini-AVR 开发替代的专用评分系统,以进行更准确的结果评估。